HPLC Analysis of Piroxicam and 2-Aminopyridine in Urine on Discovery® HS F5 after SPE using Discovery® DSC-MCAX

HPLC Analysis of Piroxicam and 2-Aminopyridine in Urine on Discovery® HS F5 after SPE using Discovery® DSC-MCAX

Conditions

sample preparation SPE (Solid Phase Extraction)
sample/matrix human urine spiked with piroxicam (4 µg/mL) and 2-aminopyridine (10 µg/mL)
SPE tube/cartridge Discovery DSC-MCAX, 100 mg/3 mL (52783-U)
condition 1 mL methanol; 1 mL 10 mM potassium phosphate, pH 3
sample addition 1 mL
washing 1 mL 10 mM potassium phosphate, pH 3; 1 mL methanol
elution 1 mL 5% ammonium hydroxide in methanol
eluate post-treatment evaporate to dryness with nitrogen at room temperature, reconstitute in 1 mL mobile phase
column Discovery HS F5, 15 cm x 4.6 mm I.D., 5 µm particles (567516-U)
column temp. 25 °C
mobile phase [A] 10 mM potassium phosphate, pH 6: [B] acetonitrile (85:15, A:B)
flow rate 2 mL/min
injection 10 µL
detector UV, 220 nm

Description

Application Sample Pre-Treatment:
Piroxicam and 2-aminopyridine (piroxicam′s polar metabolite) was spiked into human urine at the levels of 4 and 10 μg/mL, respectively. The urine sample was diluted 1:1 with 10 mM potassium phosphate, pH 3.
Categories Analytical Chromatography, SPE Applications, Clinical, Pharmaceutical Analysis, Pharmaceutical & Clinical applications, anti-inflammatories, Anti-inflammatories
Featured Industry Clinical
Legal Information Discovery is a registered trademark of Sigma-Aldrich Co. LLC
suitability application for SPE, application for HPLC

Materials

     
Related Links